Navigation Links
Amgen to Provide Testimony at FDA Hearing on Biosimilars
Date:11/1/2010

THOUSAND OAKS, Calif., Nov. 1, 2010 /PRNewswire/ -- Amgen (Nasdaq: AMGN) Senior Vice President of Research and Development Joe Miletich, M.D., Ph.D., will urge members of a U.S. Food and Drug Administration (FDA) panel charged with implementing a pathway for biosimilars to establish approval standards that ensure patient safety and follow a science-based approach.

"Put patients first and sound policy will follow," Dr. Miletich said.  "Amgen believes biosimilars have a meaningful role to play in the health care system.  However, biosimilars—unlike generic drugs—are not identical to the innovative biological products."  Getting the biosimilar pathway 'right' could benefit the future of biopharmaceuticals, whereas "imprudent policy" could simultaneously put patients unacceptably at risk, undermine the policy goals and set back the promise of new biologic treatments for patients.Noting the complexities of biological products and the likely differences in products created from different living cells, Dr. Miletich will outline three key recommendations that the FDA should consider as it moves forward:

  1. Use well-designed clinical trials to establish biosimilarity;
  2. Ensure the product manufacturer and lot number is known for all administered biological; and
  3. Set scientific and practical criteria for interchangeability.

"The question before the agency is how we can minimize patient risk and uncertainty associated with the approval of biosimilars," Dr. Miletich said.  "The challenge with biosimilars is knowing which structural variations matter clinically and which do not.  Many differences probably do not matter, while some differences are important.  Other differences remain open questions.  Clinical evaluations and experience are necessary to address these questions."'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amgen Announces Webcast of 2008 Third Quarter Financial Results
2. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
3. Call for Applications: The Amgen Award for Science Teaching Excellence
4. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
5. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
6. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
7. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
10. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... FamilyFarms Group is pleased to announce its valued ... received the 2015 Tomorrow’s Top Producer Horizon Award. The ... 35, who has demonstrated excellence in the business of ... Tomorrow's Top Producer Horizon Award. Every year I look ... and learning from their experiences. It is truly humbling ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ ... appointment of Kate Black as Privacy Officer ... international, federal, and state privacy laws as well as ... and regulatory team, she will be responsible for reviewing, ... for customers in the U.S. and abroad. She joined ...
(Date:2/26/2015)... 2015   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... Chief Executive Officer of Regulus, will present a company ... Annual Healthcare Conference on Wednesday, March 4, 2015 at ... the Boston Marriott Copley Place.  The ...
Breaking Biology Technology:Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 423andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... VMA, Confirms... -- LEUVEN, Belgium, September 1, 2010 ... ... ... // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... YORK, Aug. 31 Reportlinker.com announces that a ... catalogue: Women,s Infertility - Pipeline ... http://www.reportlinker.com/p0286181/Women,s-Infertility---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Women,s ... 2017 SummaryGlobalData, the industry analysis ...
... 31 Reportlinker.com announces that a ... in its catalogue: ... for Monoclonal Antibodies and Recombinant Proteins ... Production Technologies ...
Cached Biology Technology:Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 2Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 3Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 4Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 5Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 6Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 7Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 8Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 9Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 10Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 11Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Women's Infertility - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 2Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 3Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 4Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 5Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 6Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 7Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 8Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 9Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 10Reportlinker Adds Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies 11
(Date:2/5/2015)... --  Epic Sciences , a precision diagnostics company dedicated to ... Prahalad , Ph.D., president and CEO, is scheduled to present ... Silicon Valley, which is taking place at the Computer History ... January 26-28, 2015. Dr. Prahalad will give ... year, Epic Sciences was a finalist in the PMWC,s Most ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... professor Trey Idekera network and systems biology pioneerhas ... Prize. The Overton prize is awarded each year ... a significant contribution to the field of computational ... of Bioengineering at UC San Diego,s Jacobs School ...
... researchers at Kansas State,University, with collaboration from Epitopix ... against E. coli O157 in beef ... focus on the post-harvest food safety,aspect, whether it,s ... Thomson of,K-State,s College of Veterinary Medicine. Thomson is ...
... tracking and observing technologies are giving marine conservationists a ... that are contributing to declining fish populations, according to ... managers only such limited data as stock counts and ... sciences and lead author of the study published in ...
Cached Biology News:UC San Diego bioengineering professor trey ideker wins 2009 Overton Prize 2UC San Diego bioengineering professor trey ideker wins 2009 Overton Prize 3K-State researchers help Epitopix license the United States' first E. coli O157 vaccine for cattle 2New tracking tags are providing fish-eye views of ways to manage depressed fisheries 2
... VISION Sytem is a highly advanced ... proprietary digital imaging and automation technology ... acquisition, analysis, archving/retrieval and colored professional ... digital imaging system that aids in ...
... is specifically for electrofocusing. It ... is recommended for electrofocusing of ... or complexes that are subject ... sieving in polyacrylamide gels. Supplied ...
... is used for second-dimension SDS-PAGE sample ... place in PROTEAN Plus cells. Bromophenol ... allow monitoring of electrophoresis runs. The ... in 1x Tris, glycine, SDS, and ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
Biology Products: